Want to see IN:NURECA full AI Analyst Report?
NURECA Stock Chart & Stats
₹298.85
-₹10.75(-3.41%)
At close: 4:00 PM EST
₹298.85
-₹10.75(-3.41%)
Day’s Range― - ―
52-Week Range₹200.10 - ₹357.00
Previous CloseN/A
Volume68.50K
Average Volume (3M)1.26K
Market Cap
₹3.08B
Enterprise Value₹1.56K
Total Cash (Recent Filing)₹130.23M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)82.1
Beta1.30
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)4.12
Shares Outstanding9,541,920
10 Day Avg. Volume1,212
30 Day Avg. Volume1,262
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)1.13
Price to Sales (P/S)1.39
P/FCF Ratio116.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Owned Healthcare BrandsOwned brands give Nureca control over its product portfolio and customer-facing positioning across home healthcare categories. A focused range of diagnostic, monitoring and therapy products can support repeat distribution, broader online reach and durable brand development over the next several quarters.
Low Financial LeverageVery low leverage reduces balance-sheet risk and preserves financial flexibility, because the company has limited debt-related obligations competing with operating needs. This conservative funding profile can help Nureca withstand earnings volatility while retaining capacity to support products, inventory and distribution.
Revenue And Profit RecoveryThe return to revenue growth after earlier declines, together with profitability in the last two years, indicates improving operating stability. If sustained, this recovery can strengthen the company’s ability to reinvest in its healthcare portfolio and expand distribution while rebuilding earnings power.
Bears Say
Thin Profit MarginsVery thin margins leave limited protection against changes in product mix, discounts or operating costs, so modest execution setbacks could materially reduce earnings. The current profitability level also suggests that revenue growth has not yet translated into strong or durable returns from the business model.
Weak Cash ConversionWeak conversion of accounting profit into free cash flow limits internally generated funding for growth and reduces the reliability of reported earnings. The sharp change from prior-year cash burn also signals ongoing volatility in working capital and reinvestment requirements over the medium term.
Volatile Earnings HistoryThe history of sharp revenue declines and large earnings swings indicates that Nureca has not yet demonstrated a consistently resilient growth profile. Such volatility makes forward operating performance less predictable and increases the risk that the recent recovery may not translate into sustained profitability.
Nureca Ltd. News
NURECA FAQ
What was Nureca Ltd.’s price range in the past 12 months?
Nureca Ltd. lowest stock price was ₹200.10 and its highest was ₹357.00 in the past 12 months.
What is Nureca Ltd.’s market cap?
Nureca Ltd.’s market cap is ₹3.08B.
When is Nureca Ltd.’s upcoming earnings report date?
Nureca Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Nureca Ltd.’s earnings last quarter?
Nureca Ltd. released its earnings results on Jul 21, 2026. The company reported ₹3.214 earnings per share for the quarter.
Is Nureca Ltd. overvalued?
According to Wall Street analysts Nureca Ltd.’s price is currently Overvalued.
Does Nureca Ltd. pay dividends?
Nureca Ltd. pays a Semiannually dividend of ₹3 which represents an annual dividend yield of 0.38%. See more information on Nureca Ltd. dividends here
What is Nureca Ltd.’s EPS estimate?
Nureca Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nureca Ltd. have?
Nureca Ltd. has 9,541,920 shares outstanding.
What happened to Nureca Ltd.’s price movement after its last earnings report?
Nureca Ltd. reported an EPS of ₹3.214 in its last earnings report. Following the earnings report the stock price went up 3.564%.
Which hedge fund is a major shareholder of Nureca Ltd.?
Currently, no hedge funds are holding shares in IN:NURECA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nureca Ltd.
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditions like nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers. They also provide orthopedic aids such as massagers, pain monitoring devices, posture correctors, and rehabilitation equipment. Further offerings include humidifiers and steamers, personal weighing scales, yoga and exercise accessories, fitness trackers, and dental and personal hygiene essentials. Additionally, Nureca caters to mother and infant care with products like baby feeding accessories, carry cots, baby skincare items, and bottle warmers/sterilizers. They also supply nutritional supplements, weight management aids, and advanced monitoring devices such as ECG machines, activity trackers, and smart scales. These diverse offerings are marketed under their proprietary brands: Dr Trust, Dr Physio, and Trumom. Distribution occurs through a multi-channel approach, utilizing third-party e-commerce platforms, a network of distributors and retailers, as well as their direct-to-consumer website, drtrust.in. Established in 2016, Nureca Limited is headquartered in Chandigarh, India.
Technical Analysis
Amrutanjan Health Care Limited
―
Blue Jet Healthcare Limited
―
Procter & Gamble Health Ltd.
―
Sanofi Consumer Healthcare India Limited
―
Zota Health Care Ltd.
―








